Sign up Australia
Proactive Investors - Run By Investors For Investors
Why invest in TLT?
Theralase Technologies Inc.: THE INVESTMENT CASE

Laser specialist TheraLase Technologies primed for a pivotal year

Unlike many fledgling med-tech companies it is generating revenues and thinks there is scope to significantly increase turnover in the next few years.
Laser specialist TheraLase Technologies primed for a pivotal year
INVESTMENT OVERVIEW: TLT The Big Picture
Cold laser technology uses light to penetrate tissue to promote cellular regeneration

TheraLase Technologies Inc (CVE:TLT, OTCMKTS:TLTFF) has developed laser products to heal tissue and treat pain, although its long-term value probably lies with an early-stage, light-activated treatment for cancer.  

Unlike many fledgling med-tech companies it is generating revenues and thinks there is scope to significantly increase turnover in the next few years. A market capitalization of $43mln suggests investors are yet to fully recognize the huge potential of this hybrid business.

Therapeutic Laser Technology 

This is cold laser technology that uses light to penetrate tissue to promote cellular regeneration at the source of the injury. It effectively heals patients by eliminating pain, reducing inflammation and accelerating tissue healing.

WATCH: Here’s how it works

The equipment is used by doctors and other healthcare professionals and the company has around 600 TLC-1000 systems installed in Canada and 400 a further in the US and internationally.  

The TLC-2000 is its next- generation product backed by eight patents. Last year its kit, which is leased out, generated sales of $2mln. However, chief executive Roger Dumoulin-White reckons there is room for exponential revenue growth.   

“If you look at the Canadian and US market, so you’re looking at doctors, chiropractors, hospitals, physical therapists, you know, that type of grouping of individuals, there’s about 1.65mln in North America or in Canada and the United States,” Dumoulin-White said in a recent interview with James West of the Midas Letter.    “So at an average sale price in the $25,000 range, it quickly runs into the billions of dollars of potential for the technology.”  

The TheraLase boss thinks the business could be generating $30-$50mln annually in the next three to five years.  

Photo Dynamic Therapy

The company is developing light activated photo dynamic compounds (PDCs) to destroy cancer. This is where the compound is absorbed by the tumour and activated by light.  

A phase Ib clinical study in Canada for non-invasive bladder cancer was expected to commence in the fourth-quarter of last year focusing on a small group of patients.

The first-in-man study of TLD 1433, a water-soluble molecule, is designed to assess safety and tolerability rather than efficacy.  

A catheter will be used to fill patients’ bladders with the drug, which is left in situ for 60 minutes to allow it to localize into the cancer lesions.  

The area is then flushed before a fibre optic bundle is inserted to illuminate the bladder with a green laser light. This activates the drug that destroys the cancer.   

While uncomfortable, it is far less painful and invasive thaAnd a major milestone has now been reached.

First patient treated....

On April 4, the firm said that the first patient was treated on March 30 for non-muscle invasive bladder (NMIBC) cancer using lead compound TLD-1433.

Chief executive Roger Dumoulin-White said this "significantly" de-risked the company "by shifting it from a pre-clinical to now a clinical biotech organization in oncology".

"Theralase looks forward to successfully treating the next 2 patients and reporting out on the status of the first three patients in the study in 2Q2017," he said.

The next two patients have been enrolled in the study designed to treat three patients at a lower dose and to monitor the patients for 30 days.

If successful, then six more patients will be enrolled to be treated at a higher dose and monitored for 180 daysn the alternative treatments, which have patchy success rates.  

“It’s very, very exciting technology if we can make this work,” said Dumoulin-White.

Investigational new drug application.

Later, TheraLase expects to move the research and development process up a gear with an investigational new drug application to the Food & Drug Administration for a Phase II clinical study in the US.   

While it is still early days for the technology, peer-reviewed preclinical results have been impressive.  

“The drug has performed beyond our expectations as far as safety, tolerability and efficacy,” said Dumoulin-White.   

“We’ve seen virtually 99 to 100% kill across a wide range of cancers.   

“We’ve tried this on brain cancer, breast cancer, colorectal cancer, pancreatic cancer, prostate cancer. Same results: 100% kill, virtually no toxicity to healthy tissue.”

Immune response

Researchers have even seen what’s called an immune-mediated response. That means the laser-activated drug has prevented the recurrence of cancer by teaching the immune system how to recognize the signature of those cancer cells.  

“So, it’s a very exciting technology,” said Dumoulin-White.   

“Having said all that, everyone’s head over heels about it, the scientists, the peer reviewed publications, our scientists and clinicians.   

“Having said that, we haven’t tried it humans yet.”

Ian_55ae0ddd437b7.jpg


Register here to be notified of future TLT Company articles
View full TLT profile

Theralase Technologies Inc. Timeline

Related Articles

the word wealth seen through the lens of a pair of spectacles.
May 31 2016
The company is gaining critical mass purchasing independent financial advisers and then plugging them into its discretionary fund management operation.
Call service droids
March 09 2017
Between now and 2018, Panmure Gordon sees a compound annualised growth rate for profit in excess of 100%
Stove-with-burners.png
November 04 2016
Relationships with some of the housing industry's leading suppliers help drive sales, profit

© Proactive Investors 2017

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use